An antiviral drug slowed brain tumors in early lab tests
Original title: Preclinical evaluation of Brincidofovir in glioblastoma demonstrates improved long term-survival and cytomegalovirus-dependent and independent effects
How far along is this research?
This is a preprint. Other scientists have not checked it yet, so treat it as an early signal rather than an answer.
This was only tested in animals and in lab dishes, not in people.
The short version
An antiviral drug helped animals with brain tumors live longer in lab tests.
What was studied. Researchers tested an antiviral drug called Brincidofovir against glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary. They used a lab animal model of the tumor and tumor cells grown from patients.
What they found. The drug helped animals with the tumor live longer. It worked in two ways. It fought a virus called CMV, which is linked to tumor growth, and it also harmed tumor cells on its own. It damaged the DNA inside tumor cells. Higher doses slowed the growth of patient tumor cells more.
What this means, and what it doesn't
What it could mean: An older drug much like this one could hurt the kidneys. This newer version did not cause that harm, and it gets into cells better. That makes it worth testing further for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
What it doesn't mean: This does not mean a new treatment is ready. The work was done in animals and in lab dishes, not in people. The authors say no new therapy for this has been approved beyond standard care. This is not a cure, and no one can get this drug for a brain tumor today. Much more research must happen first.
Source: bioRxiv (preprint), August 21, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.